Abstract
Individuals affected with neurofibromatosis 1 (NF1) harbor increased numbers of GFAP-immunoreactive cerebral astrocytes and develop astrocytomas that can lead to blindness and death. Mice heterozygous for a targeted Nf1 mutation (Nf1+/−) were employed as a model for the human disease to evaluate the hypothesis that reduced NF1 protein (neurofibromin) expression may confer a growth advantage for astrocytes, such that inactivation of only one NF1 allele is sufficient for abnormal astrocyte proliferation. Here, we report that Nf1+/− mice have increased numbers of cerebral astrocytes and increased astrocyte proliferation compared to wild-type littermates. Intriguingly, primary Nf1+/− astrocyte cultures failed to demonstrate a cell-autonomous growth advantage unless they were co-cultured with C17 neuronal cells. This C17 neuronal cell-induced Nf1+/− increase in proliferation was blocked by MEK inhibition (PD98059), suggesting a p21-ras-dependent effect. Furthermore, mice heterozygous for a targeted mutation in another GAP molecule, p120-GAP, demonstrated no increases in cerebral astrocyte number. These findings suggest that reduced NF1 expression results in a cell context-dependent increase in astrocyte proliferation that may be sufficient for the development of astrocytic growth abnormalities in patients with NF1.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bader JL. . 1986 Ann. NY Acad. Sci. 486: 57–65.
Ballester R, Marchuk DA, Boguski M, Saulino AM, Letcher R, Wigler M and Collins FS. . 1990 Cell 63: 851–859.
Basu TN, Gutmann DH, Fletcher JA, Glover TW, Collins FS and Downward J. . 1992 Nature 356: 713–715.
Bollag G and McCormick F. . 1991 Ann. Rev. Cell Biol. 7: 601–632.
Bollag G, Clapp DW, Shih S, Adler F, Zhang YY, Thompson P, Lange BJ, Freedman MH, McCormick F, Jacks T and Shannon K. . 1996 Nature Genetics 12: 144–148.
Brannan CI, Perkins AS, Vogel KS, Ratner N, Nordlund ML, Reid SW, Buchberg AM, Jenkins NA, Parada LF and Copeland NG. . 1994 Genes Dev. 8: 1019–1029.
Cawthon RM, OConnell P, Buchberg AM, Viskochil D, Weiss M, Culver M, Stevens J, Jenkins NA, Copeland NG and White R. . 1990 Genomics 7: 555–565.
Daston MM, Scrable H, Norlund M, Sturbaum AK, Nissen LM and Ratner N. . 1992 Neuron 8: 415–428.
Daston MM and Ratner N. . 1993 Dev. Dyns 195: 216–226.
DeClue JE, Cohen BD and Lowy DR. . 1991 Proc. Natl Acad. Sci. USA 88: 9914–9918.
DeClue JE, Papageorge AG, Fletcher JA, Diehl SR, Ratner N, Vass WC and Lowy DR. . 1992 Cell 69: 265–273.
Eccleston PA, Bannerman PG, Pleasure DE, Winter J, Mirsky R and Jessen KR. . 1989 Development 107: 107–112.
Geist RT, Reddy AJ, Zhang J and Gutmann DH. . 1996 Neurobiol. Disease 3: 111–120.
Giordano MJ, Mahadeo DK, He YY, Geist RT, Hsu C and Gutmann DH. . 1996 J. Neuroscience Res. 43: 246–253.
Golubic M, Roudebush M, Dobrowolski S, Wolfman A and Stacey DW. . 1992 Oncogene 7: 2151–2159.
Greenwood RS, Said SM, Yeh T-L, El-Fatatry MA, Tupler LA and Krishnan KRK. . 1997 Ann. Neurol. 42: 500–501.
Guha A, Feldkamp MM, Lau N, Boss G and Pawson A. . 1997 Oncogene 15: 2755–2765.
Gutmann DH, Wood DL and Collins FS. . 1991 Proc. Natl Acad. Sci. USA 88: 9658–9662.
Gutmann DH, Geist RT, Wright DE and Snider WD. . 1995 Cell Growth Differ. 6: 315–322.
Gutmann DH, Giordano MJ, Mahadeo DK, Lau N, Silbergeld D and Guha A. . 1996 Oncogene 12: 2121–2127.
Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE, Rubinstein A and Viskochil D. . 1997 JAMA 278: 51–57.
Habiby R, Silverman B, Listernick R and Charrow J. . 1995 J. Pediatr. 126: 364–367.
Henkemeyer M, Rossi DJ, Holmyard DP, Puri MC, Mbamalu G, Harpal K, Shih TS, Jacks T and Pawson T. . 1995 Nature 377: 695–701.
Hewett SJ, Corbett JA, McDaniel ML and Choi DW. . 1993 Brain Res. 625: 337–341.
Hewett SJ, Choi DW and Gutmann DH. . 1995 Neuroreport 6: 1505–1508.
Huynh DP, Lin CT and Pulst SM. . 1992 Neuroscience Letts 143: 233–236.
Jacks T, Shih TS, Schmitt EM, Bronson RT, Bernards A and Weinberg RA. . 1994 Nature Genetics 7: 353–361.
Janeczko K. . 1988 Brain Res. 456: 280–285.
Knudson AG. . 1971 Proc. Natl Acad. Sci. USA 68: 820–823.
Largaespada DA, Brannan CI, Jenkins NA and Copeland NG. . 1996 Nature Genetics 12: 137–143.
Listernick R, Charrow J, Greenwald MJ and Esterly NB. . 1989 J. Pediatr. 114: 788–792.
Listernick R, Louis DN, Packer PJ and Gutmann DH. . 1997 Annals Neuro. 41: 143–149.
Martin GA, Viskochil D, Bollag G, McCabe PC, Crosier WJ, Haubruck H, Conroy L, Clark R, O'Connell P, Cawthon RM, Innis MA and McCormick F. . 1990 Cell 63: 843–849.
Molloy PT, Bilaniuk LT, Vaughan SN, Needle MN, Liu GT, Zackai EH and Phillips PC. . 1995 Neurology 45: 1897–1902.
Nordlund M, Gu X, Shipley MT and Ratner N. . 1993 J. Neuroscience 13: 1588–1600.
Nordlund ML, Rizvi TA, Brannan CI and Ratner N. . 1995 J. Neuropath. Exp. Neuro. 54: 588–600.
Norton KK, Xu J and Gutmann DH. . 1995a Neurobiol. Disease 2: 13–21.
Norton KK, Geist RT, Mahadeo DK and Gutmann DH. . 1995b Neuroreport 7: 601–604.
Paxinos G and Watson C. . 1986 The mouse brain in stereotaxic coordinates. 2nd Edition. Academic Press: San Diego.
Pollack IF, Schultz B and Mulvihill JJ. . 1996 Neurology 46: 1652–1660.
Riccardi VM. . 1992 Neurofibromatosis. 2nd edition. Johns Hopkins University Press: Baltimore, Maryland.
Ridley AJ, Paterson HF, Noble M and Land H. . 1989 EMBO J. 7: 1635–1645.
Rizvi TA, Akunuru S, de Courten-Myers G, Switzer RC, Nordlund ML and Ratner N. . 1999 Brain Res. 816: 111–123.
Rose K, Goldberg MP and Choi DW. . 1993 In: In Vitro Biological Systems Tyson CA and Frazier JM (eds), Academic Press pp. 46–60.
Ryder EF, Snyder EY and Cepko CL. . 1990 J. Neurobiol. 21: 356–375.
Said SMA, Yeh T-L, Greenwood RS, Whitt JK, Tupler LA and Krishnan KRR. . 1996 Neuroreport 7: 1941–1944.
Sobue G and Pleasure D. . 1984 Brain Res. 324: 175–179.
Viskochil D, Buchberg AM, Xu G, Cawthom RM, Stevens J, Wolff RK, Culver M, Carey JC, Copeland NG, Jenkins NA, White R and O'Connell P. . 1990 Cell 62: 187–192.
Wallace MR, Marchuk DA, Andersen LB, Letcher R, Odeh HM, Saulino AM, Fountain JW, Brereton A, Nicholson J, Mitchell AL, Brownstein BH and Collins FS. . 1990 Science 249: 181–186.
Weinstein DE, Shelanski ML and Liem RKH. . 1990 Glia 3: 130–139.
Xu G, Lin B, Tanaka K, Dunn D, Wood D, Gesteland R, White R, Weiss R and Tamanoi F. . 1990a Cell 63: 835–841.
Xu G, O'Connell P, Viskochil D, Cawthon R, Robertson R, Culver M, Dunn D, Stevens J, Gesteland R, White R and Weiss R. . 1990b Cell 62: 599–608.
Acknowledgements
We appreciate the advice of Drs Marga Behrens, M Livia Bajenaru, Mark Goldberg, and David Holtzman. This work was supported by funding from the NIH (NS33494) and generous support from Schnuck Markets, Inc.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gutmann, D., Loehr, A., Zhang, Y. et al. Haploinsufficiency for the neurofibromatosis 1 (NF1) tumor suppressor results in increased astrocyte proliferation. Oncogene 18, 4450–4459 (1999). https://doi.org/10.1038/sj.onc.1202829
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1202829
Keywords
This article is cited by
-
Genetic characterization of an aggressive optic nerve pilocytic glioma
Brain Tumor Pathology (2021)
-
The impact of RASopathy-associated mutations on CNS development in mice and humans
Molecular Brain (2019)
-
The rules and impact of nonsense-mediated mRNA decay in human cancers
Nature Genetics (2016)
-
Macrocephaly in neurofibromatosis type 1: a sign post for optic pathway gliomas?
Child's Nervous System (2011)
-
Glial clusters and perineuronal glial satellitosis in the basal ganglia of neurofibromatosis type 1
Acta Neuropathologica (2008)